Table 3:
Colorectal cancer (CRC) detection within 2 years of a baseline fecal immunochemical test (FIT) at various positivity thresholds by an organized outreach program using annual FIT, stratified by age and sex.
| Threshold for FIT positivity: | |||||
|---|---|---|---|---|---|
| 30 μg/g | 25 μg/g | 20 μg/ga | 15 μg/g | 10 μg/g | |
| Age 50–59 years (n=323,855) | |||||
| Cancers detected | 298/428 | 315/428 | 338/428 | 342/428 | 354/428 |
| Programmatic sensitivityb (95% CI) | 69.6% (65.0–74.0) | 73.6% (69.2–77.7) | 79.0% (74.8–82.7) | 79.9% (72.6–81.0) | 82.7% (78.8–86.2) |
| Programmatic specificityc (95% CI) | 95.3% (95.2–95.3) | 94.6% (94.5–94.6) | 93.5% (93.4–93.6) | 92.0% (91.9–92.1) | 88.7% (88.6–88.8) |
| Positive FIT at baseline or within 2 yearsd | 15,605 (4.8%) | 17,878 (5.5%) | 21,321 (6.6%) | 26,230 (8.1%) | 36,892 (11%) |
| Positive results / 1 cancer (95% CI) | 52 (47 – 59) | 57 (51 – 64) | 63 (57 – 70) | 76 (69 – 85) | 104 (94 – 116) |
| Age 60–69 years (n=234,665) | |||||
| Cancers detected | 353/534 | 370/534 | 392/534 | 403/534 | 421/534 |
| Programmatic sensitivityb (95% CI) | 66.1% (61.9–70.1) | 69.3% (65.2–73.2) | 73.4% (69.4–77.1) | 75.5% (71.6–79.1) | 78.8% (75.1–82.2) |
| Programmatic specificityc (95% CI) | 94.3% (94.2–94.4) | 93.3% (93.2–93.4) | 91.9% (91.8–92.0) | 90.0% (89.8–90.1) | 85.7% (85.6–85.9) |
| Positive FIT at baseline or within 2 yearsd | 13,745 (5.9%) | 15,955 (6.8%) | 19,355 (8.3%) | 23,897 (10%) | 33,847 (14%) |
| Positive results / 1 cancer (95% CI) | 39 (35 – 43) | 43 (39 – 48) | 49 (45 – 55) | 59 (54 – 65) | 80 (73 – 89) |
| Age 70–75 years (n=82,056) | |||||
| Cancers detected | 171/283 | 182/283 | 195/283 | 205/283 | 212/283 |
| Programmatic sensitivityb (95% CI) | 60.4% (54.5–66.2) | 64.3% (58.4–69.9) | 68.9% (63.2–74.3) | 72.4% (66.8–77.6) | 74.9% (69.4–79.9) |
| Programmatic specificityc (95% CI) | 93.3% (93.1–93.5) | 92.2% (92.0–92.4) | 90.6% (90.4–90.8) | 88.4% (88.2–88.6) | 83.7% (83.5–84.0) |
| Positive FIT at baseline or within 2 yearsd | 5,667 (6.9%) | 6,566 (8.0%) | 7,885 (9.6%) | 9,742 (12%) | 13,554 (16%) |
| Positive results / 1 cancer (95% CI) | 33 (29 – 39) | 36 (31 – 42) | 40 (35 – 47) | 48 (42 – 55) | 64 (56 – 73) |
| Men (n=303,271) | |||||
| Cancers detected | 489/717 | 517/717 | 552/717 | 562/717 | 577/717 |
| Programmatic sensitivityb (95% CI) | 68.2% (64.7–71.6) | 72.1% (68.7–75.4) | 77.0% (73.7–80.0) | 78.4% (75.2–81.3) | 80.5% (77.4–83.3) |
| Programmatic specificityc (95% CI) | 93.9% (93.8–94.0) | 93.0% (92.9–93.1) | 91.6% (91.5–91.7) | 89.7% (89.6–89.8) | 85.6% (85.5–85.7) |
| Positive FIT at baseline or within 2 yearsd | 18,899 (3.8%) | 21,654 (7.1%) | 25,932 (8.6%) | 31,814 (11%) | 44,108 (15%) |
| Positive results / 1 cancer (95% CI) | 39 (35 – 42) | 42 (39 – 42) | 47 (43 – 51) | 57 (52 – 62) | 76 (70 – 83) |
| Women (n=429,590) | |||||
| Cancers detected | 333/528 | 350/528 | 373/528 | 388/528 | 410/528 |
| Programmatic sensitivityb (95% CI) | 63.1% (58.8–67.2) | 66.3% (62.1–70.3) | 70.6% (66.6–74.5) | 73.5% (69.5–77.2) | 77.7% (73.9–81.1) |
| Programmatic specificityc (95% CI) | 95.3% (95.2–95.4) | 94.5% (94.5–94.6) | 93.4% (93.3–93.5) | 91.8% (91.7–91.9) | 88.2% (88.1–88.3) |
| Positive FIT at baseline or within 2 yearsd | 16,118 (4.8%) | 18,745 (5.6%) | 22,629 (6.7%) | 28,055 (8.3%) | 40,185 (12%) |
| Positive results / 1 cancer (95% CI) | 48 (44 – 54) | 54 (48 – 60) | 60 (55 – 67) | 72 (66 – 80) | 98 (89 – 108) |
a
The current United States conventional FIT positivity threshold is 20 μg/g
b
Among those with colorectal cancer, the proportion with a positive FIT at baseline or within 2 years
c
Among those without cancer, the proportion without a positive FIT at baseline or within 2 years
d
Individuals with a positive FIT at baseline or within 2 years